Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib-II study of MBG453 alone and with PDR001 in advanced solid tumors
jRCT2080223302Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of sabatolimab and spartalizumab in Nonhematologic neoplasms, melanoma, non-small cell lung cancer (NSCLC) and 1 more (2 arms), sponsored by Novartis. Started Aug 2016; status: completed.
02
Drugs
sabatolimabspartalizumab
03
Conditions
Nonhematologic neoplasmsmelanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2080223302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223302.